Recordati has entered into an agreement with Amdipharm for marketing and sales of TransAct LAT (local action transcutaneous) in Italy and Portugal. Its a transdermal patch containing 40mg of flurbiprofen, indicated for the symptomatic relief of localized pain involving the musculoskeletal system.
TransAct LAT is an original system for the administration of flurbiprofen, a widely prescribed non-steroidal anti-inflammatory drug (NSAID), which improves its tolerability profile, said the company.
Headquarterd in Milan, Italy, Recordati is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas.
Amdipharm makes prescription medicines available to meet clinical needs. The company specialise in marketing internationally branded products to primary and secondary care prescribers.